Proof-of-Concept with PROTACs in Prostate Cancer
Unknown authors
Abstract
Preliminary clinical data for ARV-110, a proteolysis-targeting chimera that flags the androgen receptor for degradation, indicate that the drug is safe and shows some efficacy in men with metastatic castration-resistant prostate cancer.
Topics & Concepts
Prostate cancerAndrogen receptorChimera (genetics)MedicineProteolysisCancer researchCancerDrug discoveryComputational biologyOncologyBioinformaticsBiologyInternal medicineBiochemistryGeneEnzymeProtein Degradation and InhibitorsProstate Cancer Treatment and ResearchMultiple Myeloma Research and Treatments